Tatiana De La Rosa is leaving carb-cutting behind (and scaling back her love of tequila) on compounded tirzepatide.

New rules are reshaping the telehealth market for GLP-1s like Ozempic and Wegovy, potentially impacting access to these drugs ...

An investigational injectable that only requires dosing once every 4 weeks led to substantial weight loss in patients with obesity with or without type 2 diabetes, a phase II randomized trial showed.

Study finds the GLP-1 drug liraglutide reduced migraine days by almost 50% in patients with obesity, with quality of life ...

Though much of the dust has settled around Novo Nordisk and Eli Lilly’s crusade against compounded GLP-1s, the recent ...

Maridebart cafraglutide showed promising results in weight loss, offering a monthly treatment option for obesity with ...

A current weight-loss and diabetes drug has become a surprise candidate for migraine treatment, with a new pilot study ...

A new study reports that people taking GLP-1 drugs in daily life don’t lose as much weight as those in clinical trials who take the same medications. One possible reason for the weight loss ...

An Ozempic-like drug prescribed for diabetes has been found to reduce the frequency of debilitating migraine. Researchers say ...

Insurers are cutting coverage, citing costs. But there’s seldom any discussion of the return on investment from these drugs ...

According to the CDC, 1 in 5 American adults is living with obesity. In recent years, many have turned to weight loss drugs ...

MariTide helped participants lose up to 20% of their body weight in a year-long trial. But it could be years before the new ...